This week, the Louisiana House of Representatives is holding a hearing on legislation introduced earlier this year that would authorize the state to apply for federal approval to import prescription drugs from Canada. While manufacturers strongly support increased access to affordable prescription drugs, this bill would pose a significant safety risk by exposing consumers to counterfeit and adulterated therapies. Moreover, this legislation does not deliver on a promise to lower drug costs and is not worth the risk.
To date, no secretary of the U.S. Department of Health and Human Services (HHS) has been willing to make a certification to permit drug importation. Concerns for the safety risks to U.S. consumers far outweigh the benefits, and this is well documented by Food and Drug Administration commissioners over the years. Furthermore, importing prescription drugs would not result in cost savings for consumers. The Canadian government has already stated that it will not take responsibility for the legitimacy or safety of prescription medicines exported to countries outside of Canada, leaving the financial and regulatory oversight to U.S. federal authorities and local law enforcement. Federal agencies and local law enforcement already have enough concerns when it comes to counterfeit drugs.
Consumer safety is the most important public policy concern, and the U.S. market for prescription drugs is the safest in the world. To succeed in driving down costs, our federal and state governments should support market-based policies that will support innovation and bring lifesaving medicines to patients.
The National Association of Manufacturers has a longstanding opposition to the importation of prescription drugs. Manufacturers urge Louisiana’s legislators to avoid any needless risks to public health by opposing any effort to allow for the importation or re-importation of prescription drugs.